On October 15, 2018, the Celiac Disease Foundation submitted a letter of support for the National Health Council’s (NHC) comments to the FDA’s Request for Information (RFI) regarding Standard Core Clinical Outcome Assessment and Endpoint Sets (CCOAES). The NHC’s letter to the FDA included the Foundation’s input from our medical advisory and scientific community. The…

The Celiac Disease Foundation is committed to ensuring the patient perspective is represented in celiac disease research. Through our iCureCeliac® patient registry and Patient Advocate Program, we encourage patients to engage in the research process to help shape the future of celiac disease research toward better diagnostics, treatments, and a cure. On September 20-21, 2018,…

Many patients with celiac disease have other medical conditions, such as co-occurring autoimmune disorders, requiring treatment with prescription medications. There are also several investigational treatments for celiac disease currently in the drug development pipeline that we are hopeful will be available to patients in the coming years. For these reasons, we support improved insurance coverage…

The Johnson Amendment, a provision in federal law that has protected nonprofits from becoming involved in partisan electioneering activities for the past 60+ years, is currently under threat of being substantially weakened or repealed. Maintaining political nonpartisanship is an essential component of all 501(c)(3) organizations. The Celiac Disease Foundation must remain separate from partisan politics…

On Monday, June 18, 2018, the Celiac Disease Foundation joined California nonprofit organizations in signing a letter of support for Assembly Bill 2252. There is currently no centralized state database in California where nonprofits can locate grants for which they may be eligible to apply. This leaves many nonprofits unaware of potential state agency funding…